Download PDF Introduction On October 3rd, pharmaceutical giant Eli Lilly and Company [LLY:NYSE] announced its plans to strengthen its collection of cancer drugs through the acquisition of POINT Biopharma [PNT:NASDAQ] for $1.4bn, representing a premium of almost 90%. The firm’s purchase of POINT, a clinical-stage radiopharmaceutical company with a focus Read more…
Download PDF Introduction On November 1 Johnson & Johnson, an American multinational which develops medical devices and is ranked 36 in the fortune 500 companies with yearly sales of $98.3bn, announced its proposal to acquire AbioMmed [ABMD: NASDAQ], a cardiovascular technology group. The acquisition, worth $16.6bn, will make Johnson & Read more…
Download PDF Introduction The pharmaceuticals sector has been the center of attention lately for the successful vaccines trial that finally gave some hope of recovery, even though it wasn’t without controversies. However, a lot more has been going on in the industry that might change the reputation that the industry Read more…
Impax Laboratories, Inc. (IPXL:NASDAQ) – market cap as of 27/10/2017: $1.40bn Introduction On October 17, 2017, Amneal Pharmaceuticals and Impax Laboratories announced that they will merge in an all-stock transaction. Amneal will hold c. 75% of the combined entity, whereas Impax shareholders will own the remaining stake (c. 25%). These Read more…
Teva Pharmaceuticals Industries Ltd. (TEVA); market cap (as of 02/10/2015): $51.05bn. Introduction Following a wave of consolidation in the healthcare industry, Teva Pharmaceuticals Industries Ltd. and Representaciones e Investigaciones Médicas, S.A. de C.V. (Rimsa) announced on October 1 that they have entered into a definitive agreement under which Teva Read more…
Alexion Pharmaceuticals Inc.; market cap (as of 09/05/2015): $32.54bn Synageva Biopharma Corp.; market cap (as of 09/05/2015): $7.91bn Introduction On May 6, 2015, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), the manufacturer of the world’s single most expensive prescription drug Soliris, and Synageva BioPharma Corp. (NASDAQ:GEVA) have entered into a definitive agreement Read more…
Actavis plc.; market cap (as of 21/11/2014): $70.5bn Allergan Inc.; market cap (as of 21/11/2014): $63.3bn Introduction The growing emphasis we put on health and quality of life, and the scientific advancements which are making this possible, are putting the pharmaceutical and medical industries in the spotlight. The recent surge Read more…
Valeant Pharmaceuticals International; Market Cap. (as of 3/10/2014): $42.9bn Allergan Inc.; Market Cap. (as of 3/10/2014): $53.64bn As low debt obligations alongside large cash holdings and patent expiration liabilities continue to foster a conducive environment for M&A activity in the pharmaceutical and biotech industry another multi-billion dollar struggle has emerged: Read more…
AbbVie Inc., Market Cap (as of 19/09/2014): $94.63bn Shire plc., Market Cap (as of 19/09/2014): £31.12bn In its attempt to become one of the global leaders in the rare diseases market, AbbVie successfully got the approval from Shire’s board of directors for its $54bn acquisition. This approval came after two Read more…